A Phase 1/1b Study to Evaluate the Safety and Tolerability of AB308 in Combination With AB122 in Participants With Advanced Malignancies
Latest Information Update: 10 Jun 2024
At a glance
- Drugs Ralzapastotug (Primary) ; Zimberelimab (Primary)
- Indications Cervical cancer; Diffuse large B cell lymphoma; Gastric cancer; Haematological malignancies; Malignant melanoma; Multiple myeloma; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Oesophageal cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions; First in man
- Acronyms ARC-12
- Sponsors Arcus Biosciences
- 29 May 2024 Planned End Date changed from 1 Jan 2025 to 1 Sep 2025.
- 29 May 2024 Planned primary completion date changed from 1 Jan 2025 to 1 Sep 2025.
- 27 Mar 2024 Planned End Date changed from 1 Mar 2025 to 1 Jan 2025.